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Recent studies have shown that COPD causes various extrapulmonary comorbidities.
Thus, it is important to recognize COPD not only as a respiratory disease, but also as a systemic disease 3 . Cardiovascular disease, the pathogenesis of which involves atherosclerosis, has been reported to be responsible for approximately 30 of deaths in patients with COPD 4, 5 . Furthermore, hypertension, diabetes mellitus DM , and dyslipidemia, classical risk factors for atherosclerosis, have been detected in a high proportion of COPD patients [6] [7] [8] . However, few studies have reported on comorbidities of COPD in Japan. In the present study, we focused on hypertension, DM, and dyslipidemia as comorbidities of COPD and determined their prevalence in patients with COPD compared with that in a general population.
Methods

Subjects
The COPD group in the present retrospective study consisted of 183 patients who had 
Statistical analysis
When comparing the prevalence of hypertension, DM, and dyslipidemia between COPD patients and the general population, data obtained from the National Health and Nutrition Survey for the general population in the present study were adjusted for age and gender in the COPD group using direct standardization methods. The Chi-squared test was used to compare percentages. P 0.05 was considered signi cant.
Results
Significant differences were noted in the prevalence of three comorbidities in COPD patients : 79 patients 43.2 had hypertension, 47 25.7 had dyslipidemia, and 29
15.8 had DM Table 3 . Overall, 105 patients 57.4 were found to have at least one of the three comorbidities.
The prevalence of hypertension, DM, and dyslipidemia in patients aged 50-59 years was Similarly, significant differences were found between the prevalence of hypertension and dyslipidemia / DM in patients aged 70 years. The proportion of patients with hypertension was the highest, regardless of age Table 4 . There were no signi cant differences in the prevalence of these comorbidities in patients with different stages of the disease Table 5 .
To enable comparisons with COPD patients, a general population was created by age and gender adjustment of results from the National Health and Nutrition Survey. Table 6 . Comparison of the prevalence of these conditions between the general population and the COPD patients revealed that the prevalence of DM and dyslipidemia was signi cantly higher in patients with COPD. There was no signi cant difference in the prevalence of hypertension between the two groups Fig. 1 . Fig. 1 . Comparison of prevalence of comorbidities between COPD and control groups The prevalence of hypertension was not significantly different between COPD and control groups. The prevalence of dyslipidemia and diabetes mellitus in the COPD group was signicantly higher than in the control group. H / T : hypertension, DL : dyslipidemia, DM : diabetes mellitus, n.s. : not signi cant, : p 0.001, : p 0.05
Discussion
COPD has been reported to cause various extrapulmonary comorbidities and the importance of recognizing COPD as a systemic disease has been emphasized 3 . As a comorbidity of COPD, cardiovascular disease in particular has been investigated as a cause of mortality in patients with COPD 4, 11, 12 .
Of the three comorbidities evaluated in the present study, namely hypertension, DM, and dyslipidemia, all of which are classical risk factors for atherosclerosis, hypertension was the most prevalent in patients with COPD, as reported previously [6] [7] [8] . The second most frequent comorbidity was dyslipidemia, followed by DM. The prevalence of DM and dyslipidemia was signi cantly higher in COPD patients than in the general population. The prevalence of hypertension increased with age, showing signi cant differences compared with the other comorbidities. However, there was no signi cant difference in the prevalence of hypertension between COPD patients and the general population, suggesting the in uence of age.
Recent studies have revealed the presence of systemic inflammation in patients with COPD [13] [14] [15] . Because various chronic comorbidities related to systemic inflammation have been observed, chronic systemic in ammatory syndrome has been introduced as a disease entity 16 . Therefore, in the present study, it may be that COPD-speci c systemic in ammation contributed to a significant increase in impaired glucose / lipid metabolism in patients with COPD. However, this requires further investigation, with the precise etiology and mechanisms underlying the dyslipidemia and DM in COPD patients yet to be determined.
The pathogenesis of cardiovascular disease in the presence of COPD is unclear. A recent study reported that inflammation was involved in the onset and deterioration of atherosclerosis, and so atherosclerosis has been recognized as an in ammatory disease 17 , as has COPD. In addition, many studies have suggested that systemic in ammation in COPD patients contributes to the development of cardiovascular disease [18] [19] [20] [21] [22] [23] [24] [25] . Taking these ndings into consideration, the development of cardiovascular disease in the presence of COPD may be due to an additive / synergistic effect of systemic in ammation and classical risk factors for atherosclerosis.
In the present study, approximately 60 of COPD patients had classical risk factors for atherosclerosis. In particular, the prevalence of DM and dyslipidemia was signi cantly higher in COPD patients than in the general population. Thus, controlling atherosclerosis in COPD patients may prevent the development of cardiovascular disease, subsequently improving the prognosis for these patients. Therefore, in the clinical management of COPD, screening for and the treatment of any classical risk factors for atherosclerosis may prove to be important, recognizing COPD as a systemic disorder.
